Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAPETUS: Irpagratinib + atezolizumab + bevacizumab in advanced or unresectable hepatocellular carcinoma
KCT0010558Phase 2Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irpagratinib, atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Abbisko Therapeutics. Started Mar 2026; status: recruiting.
02
Drugs
irpagratinibatezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0010558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010558.